U.S. and European Ventilators and Resuscitators Markets, New Report Launched

This market includes anesthesia delivery units, anesthesia monitors, anesthesia information management systems, anesthesia disposables, ventilators, nebulizers, respiratory disposables, oxygen therapy equipment, sleep therapy devices and sleep diagnostic devices. Dominated in value by the market for sleep therapy devices, the U.S. market for anesthesia, respiratory and sleep management devices is expected to accelerate and maintain strong growth over the forecast period.

The U.S. market for anesthesia, respiratory and sleep management devices is showing signs of sustained recovery, with particularly strong growth in sleep and oxygen therapy markets. The sleep therapy market will be driven by the growing awareness among the general population of both the symptoms of sleep apnea and the potential dangers associated with leaving the condition untreated. In addition, recent changes to the reimbursement structure for sleep diagnostics are expected to yield an increasing number of diagnostic tests.

The markets for anesthesia information management systems (AIMS) and oxygen therapy devices are also expected to grow significantly over the forecast period. There are important transitions taking place in both of these markets. Hospitals across the U.S. are installing AIMS to meet the requirements of hospital electronic medical record (EMR) legislation. In the oxygen therapy market, more expensive portable oxygen concentrators are being used to treat a growing share of ambulatory oxygen therapy patients.

Scope: This report pertains to a forecast period of 10 years (2009 - 2019) for the U.S.

Includes a U.S. Paramedeic and Advanced EMT Survey:

To provide support for the market size estimates in chapter 3 of this report, a survey of paramedics and advanced EMTs in the U.S. was conducted. Respondents were asked about the frequency with which they ventilate patients and perform cardiopulmonary resuscitation (CPR). They were also asked about the frequency with which they use specific techniques and devices.

In addition to supporting an analysis of the size of the various market segments covered in chapter 3, the survey was used to evaluate existing needs in the market for transport ventilation and CPR equipment. In a separate section of the survey, respondents were asked a diverse range of questions about manual and automatic ventilation equipment.

Spanning over 343 pages “U.S. and European Ventilators and Resuscitators Markets” report covering Executive Summary, Research Methodology, U.S. Anesthesia, Respiratory And Sleep Management Device Market Overview, Anesthesia Delivery Unit Market, Anesthesia Monitor Market, Competitive Analysis, Anesthesia Disposables Market, Ventilator Market, Competitive Analysis, Respiratory Disposables Market, Competitive Analysis, Sleep Diagnostic Device Market. This report Covered 23 Companies -Philips/Philips, Respironics, ResMed, GE Healthcare, AirSep, CareFusion, Covidien, Invacare, DeVilbiss, Fisher & Paykel, Draeger, LMA Inc., Maquet, Teleflex, Smiths Medical, King Systems, Mindray, Embla, Hamilton, Ambu, Catalina, Worthington, Precision Medical, Picis.

Know more about this report at – http://mrr.cm/ZaQ

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Chinese In-Vitro Diagnostic Reagent Market is likely to surpass 5.5 billion US dollars until 2015, finds new report

China’s regulatory framework for in-vitro diagnostic reagents is undergoing earthshaking changes. The country’s new leaders have recognized that the regulations for supervision and administration of in-vitro diagnostic reagents are far from perfect along with rapid population growth and thriving economy over the past 30 years. Chinese state council issued the latest “Regulations for the Supervision and Administration of Medical Devices” on February 12, 2014, and it has come into force as June 1, 2014. Before long, China Food and Drug Administration issued a series of the latest regulations on in-vitro diagnostic reagents on July 30, 2014 respectively, and they will come into force as October 1, 2014. The overseas in-vitro diagnostic reagents exporting into China market will be subject to administration of overall new regulations on in-vitro diagnostic reagent registration since October 1, 2014.

China is one of the fastest growing global economies with a fifth population in the world, and is one of the largest healthcare markets around the world. Along with sustained economic and population growth as well as an ageing population, Chinese healthcare market has maintained annually average growth rate above 16 % since 1990s. Among them, in-vitro diagnostic reagents represented dynamical growth since 2007. By 2013, total value of in-vitro diagnostic reagents on Chinese healthcare market has reached 3.5 billion US dollars, an increase of 22.9% over 2012 level. It is estimated that Chinese in-vitro diagnostic reagent market is likely to be more than 5.5 billion US dollars until 2015, and it is one of segment market of the most growth potentiality. The Chinese in-vitro diagnostic reagent market is attracting more and more in-vitro diagnostic reagents produced by overseas and multinational manufacturers to penetrate such market.

However, China’s radical change of regulatory framework for in-vitro diagnostic reagents will bring overseas and multinational in-vitro diagnostic reagent manufacturers the maximum challenges and opportunities. How do you in compliance with the latest Chinese regulations on in-vitro diagnostic reagents? How do you operate business smoothly in China? To enter such a lucrative in-vitro diagnostic reagent market, overseas and multinational in-vitro diagnostic reagent manufacturers must have a comprehensive and thorough knowledge of the latest Chinese regulations on in-vitro diagnostic reagent registration. Otherwise, the restrictive legal requirements and approval delays eat up your time and energy to achieve a successful entry into such a lucrative in-vitro diagnostic reagent market, and cause trouble for your business smoothly in China.

Latest Chinese Guidebook for Application and Approval of Imported In-vitro Diagnostic Reagent Registration: From Regulations to Practices (2014 Edition) not only provided a comprehensive and thorough knowledge of the latest Chinese regulations for imported in-vitro diagnostic reagent registration but also introduced the practical operation how to comply with the Chinese regulations to guide you achieve a successful approval for your products entry into the Chinese in-vitro diagnostic reagent market.

Report Highlights

• An analysis and research for radical change of Chinese regulations on in-vitro diagnostic reagents.
• An overview of the latest Chinese applicable regulations for for in-vitro diagnostic reagent registration.
• An overview of organizational structure of Chinese regulatory authorities for imported overseas in-vitro diagnostic reagent registration and recordation to give the direction of gateway for imported overseas in-vitro diagnostic reagent registration.
• The Chinese general regulations for imported overseas in-vitro diagnostic reagent registration to let overseas in-vitro diagnostic reagent manufacturer understand the unique Chinese approach for in-vitro diagnostic reagent registration and lay the knowledge foundation for the practical operation.
• The detailed Chinese classification and naming principles for in-vitro diagnostic reagents.
• The Chinese unique requirements for clinical trials of in-vitro diagnostic reagents, from the basic principles of clinical trials, the clinical trial design, scheme and methods, the sample size of clinical trial, to the clinical trial report and protocol.
• The requirements for compilation of instruction of in--vitro diagnostic reagent registration in China.
• The practical guidance for application of imported overseas in-vitro diagnostic reagent recordation, from how to compile recordation documents, how to apply for recordation to how to handle alteration recordation to smoothly navigate complex regulatory requirements step by step.
• The practical guidance for application and approval of imported overseas in-vitro diagnostic reagent registration, also from how to compile application documents, how to compile the product technical requirements, how to apply for approval of imported overseas in-vitro diagnostic reagent registration to how to submit application documents to smoothly navigate complex regulatory requirements step by step.

The practical guidance for alteration registration and renewal registration of imported overseas in-vitro diagnostic reagents, also from how to compile application documents to how to submit application documents step by step.

A complete set of full text in English of the latest Chinese regulations for imported overseas in-vitro diagnostic reagent registration, which cover  “Regulations for the Supervision and Administration of Medical Devices”, “Measures for the Administration of In Vitro Diagnostic Reagent Registration”, “Rules for Medical Device Classification”, “Technical Guidance Principles for Clinical Trials of In--vitro Diagnostic Reagents” and “Guidance Principles for Compilation of Instruction of In--vitro Diagnostic Reagents ”.

The audiences of this guidebook are overseas in-vitro diagnostic reagent manufacturers wishing to enter into the Chinese in-vitro diagnostic reagent market, and multinational in-vitro diagnostic reagent companies have penetrated into the Chinese in-vitro diagnostic reagent market, and their senior executive officers engaging in regulatory affairs expecting to understand how to apply for registration of their in-vitro diagnostic reagent products in China, how to comply with the latest Chinese regulations for in-vitro diagnostic reagent registration. After having skimmed through this guidebook, audiences can clearly acquire not only a comprehensive and thorough knowledge of the latest Chinese regulations on imported in-vitro diagnostic reagent registration but also the practical operation how to comply with the latest Chinese regulations. Access China Management Consulting Ltd hopes this guidebook, based on full and accurate regulations, can guide overseas and multinational in-vitro diagnostic reagent manufacturers and producers to achieve a successful entry into the Chinese medical device market, and smoothly operate their products in China.

Scope of the report

Latest Chinese Guidebook for Application and Approval of Imported In-vitro Diagnostic Reagent Registration: From Regulations to Practices (2014 Edition) not only provided a comprehensive and thorough knowledge of the latest Chinese regulations for imported in-vitro diagnostic reagent registration but also introduced the practical operation how to comply with the Chinese regulations to guide you achieve a successful approval for your products entry into the Chinese in-vitro diagnostic reagent market.

Chapter 2 : provides the analysis and research for radical change of Chinese regulations on in-vitro diagnostic reagents.

Chapter 3: introduces the framework of the latest Chinese applicable regulations for in-vitro diagnostic reagent registration to provide a comprehensive and thorough knowledge of the latest Chinese regulations for in-vitro diagnostic reagent registration.

Chapter 4: provides an overview of the Chinese regulatory authorities -- China Food and Drug Administration (CFDA) being responsible for approval for imported overseas in-vitro diagnostic reagent registration and recordation to give the direction of gateway for imported overseas in-vitro diagnostic reagent registration and recordation.

Chapter 5: elaborates the general regulations for imported overseas in-vitro diagnostic reagent registration to let overseas in-vitro diagnostic reagent manufacturer understand the unique Chinese approach for in-vitro diagnostic reagent registration and lay the knowledge foundation for the practical operation.

Chapter 6: elaborates the classification and naming principles for in-vitro diagnostic reagents to let overseas in-vitro diagnostic reagent manufacturer understand the Chinese in-vitro diagnostic reagent classification and nomenclature, because the imported overseas in-vitro diagnostic reagent registration must be in compliance with such classification and nomenclature of in-vitro diagnostic reagents.

Chapter 7: introduces the Chinese unique requirements for clinical trials of in-vitro diagnostic reagents, from the basic principles of clinical trials, the clinical trial design, scheme and methods, the sample size of clinical trial, to the clinical trial report and protocol step by step.

Chapter 8: introduces the requirements for compilation of instruction of in--vitro diagnostic reagent registration.

Chapter 9: introduces the regulations for application for imported in-vitro diagnostic reagent recordation, which is applicable to Class I imported overseas in-vitro diagnostic reagents.

Chapter 10: provides the regulations for application and approval for imported in-vitro diagnostic reagent registration, which is applicable to Class II and III imported overseas in-vitro diagnostic reagents.

Chapter 11: introduces the regulations for application and approval for alteration registration of imported overseas in-vitro diagnostic reagents.

Chapter 12: introduces the regulations for renewal registration of imported overseas in-vitro diagnostic reagents.

Chapter 13: introduces the regulations for supervision and administration for application and approval of imported overseas in-vitro diagnostic reagent registration and recordation.

Chapter 14: provides the practical guidance for application of imported overseas in-vitro diagnostic reagent recordation, from how to compile recordation documents, how to apply for recordation to how to handle alteration recordation to smoothly navigate complex regulatory requirements step by step.

Chapter 15: provides the practical guidance for application and approval of imported overseas in-vitro diagnostic reagent registration, also from how to compile application documents, how to compile the product technical requirements, how to apply for approval of imported overseas in-vitro diagnostic reagent registration to how to submit application documents to smoothly navigate complex regulatory requirements step by step.

Chapter 16: provides the practical guidance for alteration registration and renewal registration of imported overseas in-vitro diagnostic reagents, also from how to compile application documents to how to submit application documents step by step.

Chapter 17: Appendices provide a complete set of full text in English of the latest Chinese regulations for imported overseas in-vitro diagnostic reagent registration.

Spanning over 208 pages, “Latest Chinese Guidebook for Application and Approval of Imported In-vitro Diagnostic Reagent Registration: From Regulations to Practices (2014 Edition)” report covering the Executive Summary, Analysis and Research for Radical Change of Chinese Regulations on In Vitro Diagnostic Reagents, Latest Chinese Applicable Regulations for In-vitro Diagnostic Reagent Registration, An Overview of Chinese Regulatory Authorities for Imported In-vitro Diagnostic Reagent Registration, General Regulations for Imported In-vitro Diagnostic Reagent Registration, Classification and Naming Principles for In-vitro Diagnostic Reagents, Clinical Trials of In-vitro Diagnostic Reagents, Compilation of Instruction of In--vitro Diagnostic Reagent Registration, Application for Imported In--vitro Diagnostic Reagent Recordation, Application and Approval for Imported In--vitro Diagnostic Reagent Registration, Application and Approval for Alteration Registration of Imported In-vitro Diagnostic Reagents, Application and Approval for Renewal Registration of Imported In-vitro Diagnostic Reagents, Supervision and Administration for Application and Approval of Imported In-vitro Diagnostic Reagent Registration and Recordation, Guidance for Application of Imported In-vitro Diagnostic Reagent Recordation, Practical Guidance for Application and Approval of Imported In-vitro Diagnostic Reagent Registration, Practical Guidance for Alteration Registration and Renewal Registration of Imported In vitro Diagnostic Reagent, Appendices. The report covered 5 compnies - Life Technologies, Roche,Abbott, Siemens, Beja Asian capital

Know more about this report at – http://mrr.cm/ZaM

To browse more Medical Devices Reports visit: 

 http://www.marketresearchreports.com/medical-devices

Neuropathic Pain - Global Drug Forecast and Market Analysis to 2022, New Report Launched

Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability. New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.

Highlights

Key Questions Answered

• The neuropathic pain market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the neuropathic pain market?
• What differences exist in the current disease management across the 3 NP indications, and across the 7 markets?
• What are the views of KOLs on the present and future landscape of the neuropathic pain market?
• Several brands of neuropathic pain drugs are due for patent expiry. How will the patent expiries impact the neuropathic pain therapeutics market?
• The developmental pipeline consists of several novel drugs. Which of these drugs will attain high sales revenues during 2012-2022?

Key Findings

• The main driver for the expansion of the NP market will be the increasing NP incidence due to 2 main reasons: the growing elderly population
• And the increase in the prevalence and diagnosis of type 2 diabetes which will lead to growth of the painful diabetic neuropathy (PDN) market - the largest NP segment.
• Additionally, the approval of novel formulations and first-in-class therapies in pipeline for NP that will drive sales in this market
• The greatest barrier to growth in this market will be the fact that the key market leading drugs will go off patent during the forecast period leading to a NP market largely dominated by generics, which raises the barrier to entry for novel drug therapies.

Scope

• Overview of 3 neuropathic pain indications - painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
• Annualized neuropathic pain therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for 10 years to 2022.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the neuropathic pain therapeutics market.
• Pipeline analysis: focus on mid to late-stage pipeline drugs discussing emerging trends as well as overview of earlier phase drugs.
• Analysis of the current and future market competition in the global neuropathic pain therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
• Develop business strategies by understanding the trends shaping and driving the global neuropathic pain therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global neuropathic pain therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track drug sales in the global neuropathic pain therapeutics market from 2012-2022.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Know more about this report at – http://mrr.cm/Za5

To browse more Healthcare Reports visit:  

http://www.marketresearchreports.com/healthcare

Epilepsy - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update, New Report Launched

Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer’s Dilantin, Abbott’s Depakote, and Novartis’ Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline’s Trobalt/Potiga and Eisai’s Fycompa which both offer first-in-class mechanisms of action.

Highlights

Key Questions Answered

• Even with more than 20 AEDs on the market, there are still ~20% refractory patients. Additional unmet needs still exists in terms of safety and efficacy. Will the drugs under development fulfil the unmet needs of the epilepsy market?
• Several brands of AEDs are due for patent expiry. How will the patent expiries impact the epilepsy therapeutics market?
• The developmental pipeline consists of several novel drugs. Which of these drugs will attain high sales revenues during 2012-2022?
• What governmental changes are likely to change the epilepsy treatment landscape in the markets researched? Which is the biggest growth market globally?

Key Findings

• New market entrants particularly Fycompa, Trobalt/Potiga and brivaracetam will increase competitiveness and cannibalize sales of existing AEDs.
• Drivers for market growth will include the introduction of the newer epilepsy drugs into the Asian market, particularly in Japan.
• Government cost-cutting measures will negatively impact epilepsy drug market in the EU

Scope

• Overview of epilepsy, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
• Annualized epilepsy therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the epilepsy therapeutics market.
• Pipeline analysis: comprehensive data split across different phases, emerging trends and mechanisms of action under development, including ion channel modulators, GABA modulators, glutamate receptor antagonists, inflammation inhibitors, synaptic and gap junction blockers, sigma receptor agonists and acetylcholine modulators.
• Analysis of the current and future market competition in the global epilepsy therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global epilepsy therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global epilepsy therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track drug sales in the global epilepsy therapeutics market from 2012-2022.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Know more about this report at – http://mrr.cm/ZaS

To browse more Diseases Reports visit:  

http://www.marketresearchreports.com/diseases

Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023, New Report Launched

Product Launches and Patent Expiries to Push Major Depressive Disorder Treatment Market through Fluctuating Growth Period by 2023

The therapeutics market for Major Depressive Disorder (MDD) will face a dynamic phase up until the end of 2023, thanks to the potential launch of new treatments following the patent expirations of top-selling products, according to new report.

The PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023 report, the MDD treatment market achieved sales of approximately $9.3 billion in 2013 across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan) and Australia. These sales will witness minimal growth by the end of 2023, reaching an estimated $9.7 billion, at a Compound Annual Growth Rate (CAGR) of 0.39%.

However, The forecasts that the market value will first undergo a decline until 2017, with sales dropping to $7.3 billion. This can be attributed mainly to the expirations of patents for Eli Lilly’s Cymbalta, Otsuka Pharmaceutical/BMS’ Abilify and AstraZeneca’s Seroquel XR.

The Senior Analyst covering Neurology, says: “Additionally, there are a number of significant needs in the depression therapeutics market that are yet to be addressed. These include the requirement for products that demonstrate improved efficacy, more favorable safety profiles and a rapid onset of antidepressant effects. Ample opportunity therefore exists for players looking to develop and potentially introduce therapies, which can address these unmet needs, into this arena.”

Publisher states that there are already seven products in the late-stage pipeline that could enter the MDD market during the forecast period. These include adjunctive therapies, such as Otsuka/Lundbeck’s brexpiprazole, Forest (Actavis)/Gedeon Richter/Mitsubishi Tanabe Pharma’s cariprazine, Alkermes’s ALKS-5461 and Naurex’s GLYX-13, along with antidepressant therapies, including Euthymics Bioscience’s amitifadine, Lundbeck/Takeda’s tedatioxetine and e-Therapeutics’ ETS6103.

The Senior Analyst continues: “All seven of these pipeline drugs show promise as safer and more efficacious treatments for MDD patients, while GLYX-13 and ETS6103 in particular boast the potential to provide rapid antidepressant effects.

“With their ability to address some of the MDD treatment market’s key unmet needs, we believe that these products’ launches could well spark its return to growth in 2018. Other driving factors behind the reversal in its decline will be the increasing uptake of Lundbeck/Takeda’s Brintellix, combined with the expanding number of MDD prevalent cases that we expect to see by the end of 2023.”

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023 report provides an overview of Major Depressive Disorder (MDD), including epidemiology, etiology, pathophysiology, symptoms, diagnosis and current treatment options. The key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the MDD therapeutics market.

Know more about this report at – http://mrr.cm/Za3

To browse more Pharma and Healthcare Reports visit:  

http://www.marketresearchreports.com/pharma-healthcare

About Market Research Reports, Inc.

Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update, New Report Launched

PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update report Provide Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing a direct-acting antiviral (DAA), such as Gilead's Sovaldi (sofosbuvir) or Janssen's Olysio (simeprevir), along with pegylated interferon (e.g., Roche’s Pegasys and Merck’s PegIntron) and/or ribavirin (e.g., Roche’s Copegus and Merck’s Rebetol) are used to treat HCV infections. Sovaldi and Olysio have largely replaced first-generation NS3/4A protease inhibitors, such as Vertex's Incivek (telaprevir) and Merck's Victrelis (boceprevir) due to their increased tolerability, efficacy, and shorter treatment duration. The entrance of next-generation , all-oral HCV therapies is expected to fundamentally alter the HCV treatment algorithm.

Highlights

Key Questions Answered

• How quickly, and to what extent, will interferon-sparing and all-oral regimens replace Incivek and Victrelis in the treatment algorithm?
• What role, if any, will interferon-based therapies have in the HCV treatment landscape over the next decade?
• Which novel HCV therapies will face adoption challenges in the market? What is the projected uptake of new drugs, such as Merck’s MK-5172/MK-8742, over the forecast period?
• Will the reduced pill burden and increased convenience of fixed-dose, all-oral combination therapies lead to their widespread uptake?
• How will pricing influence the use of next-generation DAAs?
• Which HCV regimen(s) in development are physicians most excited about?

Key Findings

• Patient awareness is anticipated to increase in response to government education and screening initiatives.
• Interferon use is predicted to drastically decrease over the next 10 years.
• The launch of next-generation, all-oral DAA regimens is expected to streamline the HCV treatment algorithm.
• The approval of more-tolerable HCV therapies is likely to result in patients deciding to undergo treatment (i.e., decrease in the warehouse effect).
• Fixed-dose combination therapies are expected to seize market share due to their reduced pill burden and convenience.

Scope

• Overview of hepatitis C virus (HCV), including epidemiology, etiology, general symptoms from infection, and national vaccination recommendations and guidelines.
• Annualized HCV therapeutics market revenue, annual cost of therapy, and treatment usage pattern data from 2012 and forecast for 10 years to 2022.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HCV market.
• Pipeline analysis: comprehensive data split across different phases, and emerging trends, specifically interferon-free therapies and fixed-dose combinations.
• Analysis of the current and future market competition in the global HCV therapeutics market. Insightful review of the key industry and governmental drivers, restraints and challenges.
• Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global HCV therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HCV market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track drug sales in the global HCV therapeutics market from 2012-2022.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Know more about this report at – http://mrr.cm/Zaw

To browse more Pharma and Healthcare Reports visit:  

http://www.marketresearchreports.com/pharma-healthcare

Allergic Rhinitis - Epidemiology Forecast to 2023, New Report Launched

Allergic rhinitis is a chronic respiratory disease characterized by inflammation of the nasal cavity and affects people of all ages. The main symptoms of allergic rhinitis are sneezing, nasal itching, blocked or runny nose and sore throat. Research suggests that a combination of genetic factors such as family history of allergic rhinitis and environmental factors such as exposure to allergens, including smoke, dust, pollen, insects, molds, or animal dander, may increase the risk for developing allergic rhinitis.

According to Publisher’s epidemiological forecast, the total prevalent cases of allergic rhinitis in the 7MM will increase from 123,273,876 total prevalent cases in 2013 to 125,427,387 total prevalent cases in 2023, at an annual growth rate of 0.17% during the forecast period.

In 2023, the US will have the highest number of the total prevalent cases of allergic rhinitis with 39,031,365 total prevalent cases, followed by Japan with 36,602,227 total prevalent cases.

To forecast the total prevalent cases of allergic rhinitis in the 7MM, publisher epidemiologists selected only nationally representative studies that provided total prevalence of allergic rhinitis using uniform diagnostic criteria based on self-reported prevalence of allergic rhinitis. The use of studies that provided uniform diagnostic criteria for total prevalence of allergic rhinitis facilitated meaningful comparison of the forecast total prevalent cases of allergic rhinitis across the 7MM. Furthermore, Publisher epidemiologists provided a comprehensive forecast of the total prevalent cases of allergic rhinitis segmented by severity (mild, moderate, and severe) as well as type (seasonal, perennial, and both).

Scope

• The Allergic Rhinitis EpiCast Report provide an overview of the risk factors, comorbidities, and the global and historical trends of allergic rhinitis in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the total prevalent cases of allergic rhinitis segmented by sex and age (ages =18 years).
• The allergic rhinitis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
• The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

• Develop business strategies by understanding the trends shaping and driving the global allergic rhinitis market.
• Quantify patient populations in the global allergic rhinitis market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for allergic rhinitis therapeutics in each of the markets covered.

Know more about this report at – http://mrr.cm/Zai

To browse more Healthcare Reports visit:  

http://www.marketresearchreports.com/healthcare

Ebola Viral Infections - Pipeline Review, H1 2014, New Report Launched

Ebola Viral Infections - Pipeline Review, H1 2014 report provides an overview of the Ebola Viral Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola Viral Infections and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products..

Scope

• The report provides a snapshot of the global therapeutic landscape of Ebola Viral Infections
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities.
• The report reviews key players involved in the therapeutics development for Ebola Viral Infections and enlists all their major and minor projects
• A review of the Ebola Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• Coverage of the Ebola Viral Infections pipeline on the basis of target, MoA, route of administration and molecule type

Reasons to Buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Identify and understand important and diverse types of therapeutics under development for Ebola Viral Infections
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Spanning over 70 pages, “Ebola Viral Infections - Pipeline Review, H1 2014” report covering the Introduction, Ebola Viral Infections Overview, Therapeutics Development, Pipeline Products for Ebola Viral Infections - Overview, Pipeline Products for Ebola Viral Infections - Comparative Analysis, Drug Profiles, Appendix, Methodology. The report covered 8 companies - Tekmira Pharmaceuticals Corp., Toyama Chemical Co., Ltd., Medicago Inc., Zalicus Inc., Summit Corporation plc, Vaxart, Inc., Navigen Pharmaceuticals, Inc., Humabs BioMed SA

Know more about this report at – http://mrr.cm/ZaJ

To browse more Diseases Reports visit:  http://www.marketresearchreports.com/diseases

Iron Deficiency Anemia - Pipeline Review, H2 2014, New Report Launched

Iron Deficiency Anemia - Pipeline Review, H2 2014 report provides an overview of the Iron Deficiency Anemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Iron Deficiency Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

It also reviews key players involved in the therapeutic development for Iron Deficiency Anemia and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

• The report provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Iron Deficiency Anemia and enlists all their major and minor projects
• A review of the Iron Deficiency Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• Coverage of the Iron Deficiency Anemia pipeline on the basis of target, MoA, route of administration and molecule type

Reasons to Buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Iron Deficiency Anemia
• Devise corrective measures for pipeline projects by understanding Iron Deficiency Anemia pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Spanning over 60 pages, “Iron Deficiency Anemia - Pipeline Review, H2 2014” report covering the Introduction, Therapeutics Development, Pipeline Products for Iron Deficiency Anemia - Overview, Pipeline Products for Iron Deficiency Anemia - Comparative Analysis, Drug Profiles, Appendix and Methodology.

Know more about this report at – http://mrr.cm/Zao

To browse more Pharma and Healthcare Reports visit:  

http://www.marketresearchreports.com/pharma-healthcare

Neutrogin - Drug Insights, 2014, New Report Launched

Neutrogin - Drug Insights, 2014 report provides Neutrogin marketed details and API Manufacturers details across the globe along with the location. In addition, it covers sales estimates for the US, detailed clinical assessment of the drug, patent details, route of synthesis, competitive landscape, and analysis of sales performance during the forecast period (2011-2015). The report also includes SWOT analysis for the drug. This report is built using data and information sourced from Publisher proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by Publisher team of industry experts.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Publisher team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Scope

• A review of the Neutrogin based on information derived from company and industry-specific sources
• Coverage of the Marketed data of the Neutrogin on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification
• Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and API Manufactures in China & India for Schizophrenia drugs with location details
• Patent Expiry Timeline and Exclusivity Details
• Route of Synthesis of the API
• Global Forecasted Sales Figure from 2011-2015
• Qualitative and quantitative assessment of market space
• SWOT Analysis

Reasons to buy 

• Evaluate the marketing status and exclusivity details of Neutrogin to exploit opportunities for generic drug development opportunities.
• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Neutrogin.
• API intelligence over Neutrogin and gaining primary intelligence over Active Ingredients manufacturers across the globe.
• Understanding the chemical route of synthesis of Neutrogin.
• Uncovering opportunities in the rapidly growing the US market
• Stay ahead of competition by understanding the changing competitive landscape
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
• Obtain sales forecast for currently marketed drug for 2011-2015

Spanning over 35 pages, “Neutrogin - Drug Insights, 2014” report covering the Drug Overview, Global API Manufacturers Assessment, The Pipeline Coverage, Company Profile, Summary, SWOT Analysis, Appendix, Methodology.

Know more about this report at – http://mrr.cm/Zbx

Related Reports:

1st - Combivir-Drug Insights, 2014- visit at: http://mrr.cm/Zbf

2nd - Rocephin-Drug Insights, 2014 - visit at: http://mrr.cm/ZbY

3rd - Halaven-Drug Insights, 2014- visit at: http://mrr.cm/Zbg

To browse more market research reports by Delveinsight visit: http://www.marketresearchreports.com/publisher/delveinsight